3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
8
Terminated
2
Withdrawn
1
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
4
Breast Neoplasms
3
Sarcoma
2
Neoplasms
2
Glioblastoma
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Localized Resectable Adult Primary Liver Cancer
1
Jaundice
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Colonic Neoplasms
1
Clinical Stage I Gastric Cancer AJCC v8
1
Childhood Brain Neoplasm
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Biliary Tract Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
2
Fluorouracil
2
tremelimumab
1
pembrolizumab
1
monalizumab
1
epacadostat
1
durvalumab
1
Surgical Procedures, Operative
1
Nivolumab
1
Metabolic Networks and Pathways
1
Leucovorin
1
Immune Checkpoint Inhibitors
1
Fecal Microbiota Transplantation
1
Biopsy
1
AMG 337
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma Of Esophagus
×
Surgical Procedures, Operative
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn